Literature DB >> 31186733

Effect of the Nrf2-ARE signaling pathway on biological characteristics and sensitivity to sunitinib in renal cell carcinoma.

Shiliang Ji1, Yufeng Xiong2, Xingxing Zhao3, Yanli Liu4, Li Qiang Yu5.   

Abstract

The aim of the present study was to examine the effects of the nuclear factor erythroid-2 related factor 2-antioxidant-responsive element (Nrf2-ARE) signaling pathway on the biological characteristics and sensitivity to targeted therapy in human renal cell carcinoma (RCC) cells. RCC tissues and adjacent tissues were collected and assessed by immunohistochemistry to determine the expression of Nrf2, NAD(P)H dehydrogenase [quinone] 1 (NQO1) and heme oxygenase-1 (HO-1) to analyze the clinicopathological features of RCC. A series of in vitro experiments were conducted to analyze the biological characteristics of Nrf2-ARE signaling in RCC. The renal cancer cell line, 786-0 was used, and cells was divided into a mock group, negative control group and small hairpin (sh)RNA-Nrf2 group. A Cell Counting Kit-8 assay was performed alongside flow cytometry to detect cell viability, cell cycle stage and apoptosis following treatment with sunitinib. The results demonstrated that Nrf2, NQO1 and HO-1 were significantly upregulated in RCC tissues compared with adjacent tissues and were associated with tumor node metastasis stage, Fuhrman classification and lymph node metastasis. Following shRNA-Nrf2 transfection, the 786-0 cells demonstrated a significant decrease in viability, cell invasion and scratch healing rate, and the mRNA and protein expression levels of Nrf2, NQO1, HO-1 and glutathione transferase were significantly decreased, which enhanced the sensitivity to sunitinib, arrested cells in the G0/G1 phase and increased apoptosis. In conclusion, Nrf2-ARE signaling is important for RCC progression, and its inhibition may increase sensitivity to targeted drugs to provide novel developments for RCC treatment.

Entities:  

Keywords:  786-0 cells; nuclear factor erythroid-2 related factor 2-antioxidant-responsive element signaling pathway; oncotherapy; sunitinib

Year:  2019        PMID: 31186733      PMCID: PMC6507454          DOI: 10.3892/ol.2019.10156

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  60 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

Authors:  F Chang; J T Lee; P M Navolanic; L S Steelman; J G Shelton; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

3.  BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.

Authors:  Ern Yu Tan; Leticia Campo; Cheng Han; Helen Turley; Francesco Pezzella; Kevin C Gatter; Adrian L Harris; Stephen B Fox
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

4.  Protection of chlorophyllin against oxidative damage by inducing HO-1 and NQO1 expression mediated by PI3K/Akt and Nrf2.

Authors:  Yanlin Zhang; Li Guan; Xifu Wang; Tao Wen; Junjie Xing; Jinyuan Zhao
Journal:  Free Radic Res       Date:  2008-04

Review 5.  The epidemiology of renal cell carcinoma.

Authors:  Loren Lipworth; Robert E Tarone; Joseph K McLaughlin
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

Review 6.  Activation of the PI3K/Akt pathway and chemotherapeutic resistance.

Authors:  Kip A West; S Sianna Castillo; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2002-12       Impact factor: 18.500

7.  Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage.

Authors:  Ju Hee Lim; Kyeong-Man Kim; Seong Who Kim; Onyou Hwang; Hyun Jin Choi
Journal:  Pharmacol Res       Date:  2008-03-22       Impact factor: 7.658

8.  Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin.

Authors:  Hak-Ryul Kim; Sejin Kim; Eun-Jung Kim; Jung-Hyun Park; Sei-Hoon Yang; Eun-Taik Jeong; Channy Park; Myung-Ja Youn; Hong-Seob So; Raekil Park
Journal:  Lung Cancer       Date:  2007-11-19       Impact factor: 5.705

Review 9.  The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease.

Authors:  Marcus J Calkins; Delinda A Johnson; Jessica A Townsend; Marcelo R Vargas; James A Dowell; Tracy P Williamson; Andrew D Kraft; Jong-Min Lee; Jiang Li; Jeffrey A Johnson
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

Review 10.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.

Authors:  Kiran Gupta; Jeffrey D Miller; Jim Z Li; Mason W Russell; Claudie Charbonneau
Journal:  Cancer Treat Rev       Date:  2008-03-04       Impact factor: 12.111

View more
  5 in total

1.  Integrative clinical and molecular characterization of translocation renal cell carcinoma.

Authors:  Ziad Bakouny; Ananthan Sadagopan; Praful Ravi; Nebiyou Y Metaferia; Jiao Li; Shatha AbuHammad; Stephen Tang; Thomas Denize; Emma R Garner; Xin Gao; David A Braun; Laure Hirsch; John A Steinharter; Gabrielle Bouchard; Emily Walton; Destiny West; Chris Labaki; Shaan Dudani; Chun-Loo Gan; Vidyalakshmi Sethunath; Filipe L F Carvalho; Alma Imamovic; Cora Ricker; Natalie I Vokes; Jackson Nyman; Jacob E Berchuck; Jihye Park; Michelle S Hirsch; Rizwan Haq; Gwo-Shu Mary Lee; Bradley A McGregor; Steven L Chang; Adam S Feldman; Catherine J Wu; David F McDermott; Daniel Y C Heng; Sabina Signoretti; Eliezer M Van Allen; Toni K Choueiri; Srinivas R Viswanathan
Journal:  Cell Rep       Date:  2022-01-04       Impact factor: 9.995

Review 2.  The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors.

Authors:  Sanja Mijatović; Ana Savić-Radojević; Marija Plješa-Ercegovac; Tatjana Simić; Ferdinando Nicoletti; Danijela Maksimović-Ivanić
Journal:  Antioxidants (Basel)       Date:  2020-04-30

Review 3.  Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies.

Authors:  Poornima Paramasivan; Ibrahim H Kankia; Simon P Langdon; Yusuf Y Deeni
Journal:  Cancer Drug Resist       Date:  2019-09-19

4.  Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression.

Authors:  Vincenzo Quagliariello; Massimiliano Berretta; Simona Buccolo; Martina Iovine; Andrea Paccone; Ernesta Cavalcanti; Rosaria Taibi; Monica Montopoli; Gerardo Botti; Nicola Maurea
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

5.  Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine.

Authors:  Roy Elias; Akanksha Sharma; Nirmish Singla; James Brugarolas
Journal:  Kidney Cancer J       Date:  2019
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.